More News! For those who want to keep up with everything

More News! 1 Mar 2017

German Spin-off Scores Funding to Treat Atrial Fibrillation

The Berlin-based startup OMEICOS Therapeutics announced the first closing of a series B financing round of €8.3M and the initiation of a Phase 1 clinical trial for the treatment of atrial fibrillation. OMEICOS Therapeutics, a spin-off from the Max Delbrueck Center for Molecular Medicine in Berlin, is taking the next step with its lead compound OMT-28 for […]

March 1, 2017 - 3 minutesmins - By Melanie De Almeida

cultured meat market 2020 1 e1488366878713

More News! 1 Mar 2017

Lab-Grown Meat Could Hit the Market as Soon as 2020

Cultured meat could be a sustainable, healthy and inexpensive food alternative in a future that might be closer than we think. We recently attended the 2nd International Conference on Cultured Meat, where we had the chance to meet the key players in this revolutionary field. There, we learned that cultured meat, grown in the lab without […]

March 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

UK Physical Sciences Rosalind Franklin Research Institute 1

More News! 27 Feb 2017

UK Lays Down a Foundation for Physical Science Innovation

The UK government announced a €117M (£100M) investment to join the forces in physical sciences, engineering and life sciences through the new Rosalind Franklin research institute (RFI). Rosalind Franklin, the British scientist whose use of X-rays to study biological structures played a crucial role in the discovery of the DNA ‘double helix’, has laid some of the cornerstones in biophysical […]

February 27, 2017 - 2 minutesmins - By Melanie De Almeida

Congenica Sapientia fundraising clinical genomics e1487935960201

More News! 27 Feb 2017

Fundraising in the UK will Support Rare Disease Diagnostics Worldwide

Congenica has raised £8M in its Series B financing round to sustain the international rollout of its clinical genome analysis platform Sapientia. Congenica is a genomic diagnostics company in Cambridge’s biotech cluster. Its genome analysis platform, Sapientia, takes on the challenge of interpreting the avalanche of genomic data becoming available in healthcare. The £8M (€9.5M) raised will sustain the […]

February 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

bidirectional neuroprosthesis university of geneva unige

More News! 24 Feb 2017

Interfacing the Brain & Machines: Another Step to a Cyborg Future

Controlling robotic prostheses with one’s mind has been a hot topic in research, but making a prothesis ‘talk back’ has been a stumbling block. Researchers from Switzerland show progress in creating sensations from a bidirectional neuroprosthesis. Researchers from the University of Geneva, in Switzerland, are developing a new method to connect a prosthesis to neural activity […]

February 24, 2017 - 3 minutesmins - By Denise Neves Gameiro

Acacia Pharma Phase III Post Operative Nausea

More News! 13 Feb 2017

To the Rescue: A Final Phase III Success for Post-Operative Nausea

The dopamine antagonist Baremsis is on its way to FDA approval for the treatment and prophylaxis of post-operative nausea & vomiting, after succeeding in a final phase III study. Acacia Pharma, one of our Cambridge top 15 biotechs, is repurposing marketed drugs to provide supportive treatments for post-surgical or cancer patients. Their lead project, Baremsis, is a dopamine antagonist, which Acacia is […]

February 13, 2017 - 3 minutesmins - By Melanie De Almeida

More News! 11 Feb 2017

This Musician Plays Piano Duets with a Microorganism

Eduardo Miranda researches, composes and performs contemporary music at the interface of biology, computing and the human mind. Eduardo Miranda, Professor of Computer Music at Plymouth University, is the first person to ever compose and perform a piano piece for a human and a microorganism. To allow the tiny creature to play with him, Miranda […]

February 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

More News! 9 Feb 2017

After its First Success, the Virtual Biotech Team is Back at it Again

SuperX has raised €10.3M ($11M) in Series A from Medicxi and J&J Innovation to develop anticoagulant antibodies for stroke and heart attacks. The team behind XO1, which was acquired by J&J’s Janssen back in 2015, is repeating the whole process again. Their new company, SuperX, is also focused on the discovery of anticoagulant antibodies to treat […]

February 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 8 Feb 2017

The First Stroke Drug in Decades? French Biotech gets closer to the Clinic

Acticor Biotech has raised €1.5M from CapDecisif Management, which will help its candidate for acute ischemic stroke enter Phase I trials. Acticor Biotech is a spin-off from the French National Institute of Health and Medical Research (Inserm) focusing on treating the acute phase of ischemic stroke, which occurs within the first few hours. The French VC firm CapDecisif Management has seen promise in […]

February 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 8 Feb 2017

The FDA lays down Laws of Interchangeability: New Era for Biosimilars?

The new guidelines from the FDA on interchangeability may bring the US biosimilar market up to speed and a new opportunity for European companies. Though the US has long been seen as the most promising market for biosimilars due to the size of the market and high drug prices driving an interest in more affordable options, […]

February 8, 2017 - 4 minutesmins - By External Contributor

More News! 4 Feb 2017

This PhD-Carrying Musician Tells the Story of Life through Music & Video

Max Cooper bridges the age-old divide between science and art with a transfixing blend of glitchy electronica, classical music and haunting vocals. I was lucky enough to catch Max Cooper live in Dublin last weekend, during his tour to showcase his latest album, Emergence. Inspired by natural processes and the laws underlying them, Emergence is a tour-de-force of […]

February 4, 2017 - 6 minutesmins - By Evelyn Warner

More News! 2 Feb 2017

Galapagos kicks off a Phase IIa trial for Cystic Fibrosis

After Galapagos and AbbVie expanded their collaboration on cystic fibrosis, Galapagos now announces the start of their Phase IIa trial for a novel cystic fibrosis corrector. Since entering their collaboration with AbbVie on cystic fibrosis (CF) in 2013, Galapagos has received almost €40M in milestone payments from AbbVie. Galapagos now announced the start of a Phase […]

February 2, 2017 - 2 minutesmins - By Melanie De Almeida

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us